

## Review Article

# Associations of *KCNQ1* Polymorphisms with the Risk of Type 2 Diabetes Mellitus: An Updated Meta-Analysis with Trial Sequential Analysis

Xiao-xuan Yu <sup>1</sup>, Min-qi Liao <sup>1</sup>, Yu-fei Zeng<sup>2</sup>, Xu-ping Gao <sup>1</sup>, Yan-hua Liu,<sup>3</sup> Wei Sun,<sup>4</sup> Sui Zhu,<sup>5</sup> Fang-fang Zeng <sup>1</sup>, and Yan-bin Ye <sup>6</sup>

<sup>1</sup>Department of Epidemiology, School of Medicine, Jinan University, No. 601 Huangpu Road West, Guangzhou, 510632 Guangdong, China

<sup>2</sup>Department of Obstetrics and Gynecology, Shangrao Fifth People's Hospital, Shangrao, Jiangxi 334000, China

<sup>3</sup>The First Affiliated Hospital of Zhengzhou University, No. 1 East Jianshe Road, Zhengzhou, 450052 Henan, China

<sup>4</sup>Customs Comprehensive Laboratory, Baiyun International Airport Customs, Hengyi Road, Guangzhou, 510080 Guangdong, China

<sup>5</sup>Department of Medical Statistics, School of Medicine, Jinan University, No. 601 Huangpu Road West, Guangzhou, 510632 Guangdong, China

<sup>6</sup>Department of Nutrition, The First Affiliated Hospital of Sun Yat-sen University, 58# Zhongshan Road 2, Guangzhou, 510080 Guangdong, China

Correspondence should be addressed to Fang-fang Zeng; zengffjnu@126.com and Yan-bin Ye; yanbinye72@163.com

Received 30 November 2019; Revised 10 April 2020; Accepted 28 April 2020; Published 6 July 2020

Academic Editor: Claudia Cardoso

Copyright © 2020 Xiao-xuan Yu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Background.** Previous studies have examined the role of the KQT-like subfamily Q member1 (*KCNQ1*) gene polymorphisms on the risk of type 2 diabetes mellitus (T2DM), but the findings are inconclusive. **Objective.** To examine the association between the *KCNQ1* gene polymorphisms and the risk of T2DM using an updated meta-analysis with an almost tripled number of studies. **Methods.** Five electronic databases, such as PubMed and Embase, were searched thoroughly for relevant studies on the associations between seven most studied *KCNQ1* gene polymorphisms, including rs2237892, rs2237897, rs2237895, rs2283228, rs231362, rs151290, and rs2074196, and T2DM risk up to September 14, 2019. The summary odds ratios (ORs) with their 95% confidence intervals (CIs) were applied to assess the strength of associations in the random-effects models. We used the trial sequential analysis (TSA) to measure the robustness of the evidence. **Results.** 49 publications including 55 case-control studies (68,378 cases and 66,673 controls) were finally enrolled. In overall analyses, generally, increased T2DM risk was detected for rs2237892, rs2237895, rs2283228, rs151290, and rs2074196, but not for rs231362 under all genetic models. The ORs and 95% CIs for allelic comparison were 1.23 (1.14-1.33) for rs2237892, 1.21 (1.16-1.27) for rs2237895, 1.27 (1.11-1.46) for rs2237897, 1.25 (1.09-1.42) for rs2283228, 1.14 (1.03-1.27) for rs151290, 1.31 (1.23-1.39) for rs2074196, and 1.16 (0.83, 1.61) for rs231362. Stratified analyses showed that associations for rs2237892, rs2237895, rs2283228, and rs151290 were more evident among Asians than Caucasians. TSA demonstrated that the evidence was sufficient for all polymorphisms in this study. The genotypes of the three SNPs (rs2237892, rs2283228, and rs231362) were significantly correlated with altered *KCNQ1* gene expression. **Conclusion.** This meta-analysis suggested that *KCNQ1* gene polymorphisms (rs2237892, rs2283228, rs2237895, rs151290, and rs2074196) might be the susceptible factors for T2DM, especially among Asian population.

## 1. Introduction

The global epidemic of diabetes is a major public health problem, and the number of cases has increased four times

in the past 30 years [1]. Incredibly, 1 in 11 adults suffered diabetes globally. It is estimated that about 463 million adults were living with diabetes mellitus worldwide in 2019, and most of them had type 2 diabetes mellitus (T2DM).

Moreover, this number is expected to increase to 642 million by 2040 [2]. Considering its high prevalence and rapid increasing speed, there are increasing numbers of investigations focusing on risk factors and susceptibilities for T2DM. However, the underlying etiology of T2DM remains unclear. Therefore, we conducted this meta-analysis to further demonstrate whether genetic factors play a vital role in the pathogenesis of T2DM [3] or not.

KQT-like subfamily Q member1 (*KCNQ1*) is a family of voltage-gated potassium channels, and the *KCNQ1* gene located on 11p15.5 encoded the protein [4]. Although *KCNQ1* is mainly expressed in the tissues or cells in the heart, it is also expressed in other tissues or organs such as pancreas islets [5]. Blockading the channels with *KCNQ1* inhibitors, 293B might stimulate secretion of insulin in pancreas, suggesting the effect of *KCNQ1* on the regulation of insulin secretion [6].

Unoki et al. [7], firstly, noted that populations with *KCNQ1* gene polymorphisms were susceptible to T2DM. Since then, many studies have explored the roles of *KCNQ1* gene polymorphisms on T2DM risk, but their findings were inconsistent. These discrepancies might be attributable to the various types of research populations and different sample sizes across studies. The statistical testing power of a single study may not be enough to detect the small effect. Therefore, it is necessary to conduct a comprehensive analysis on the association between the *KCNQ1* polymorphisms and the risk of T2DM. Therefore, in 2013, a meta-analysis of Liu et al. [8] consequently suggested that *KCNQ1* rs2237892, rs2237897, rs2237895, rs2283228, and rs231362 polymorphisms were associated with increased T2DM risk. Nevertheless, this meta-analysis only paid attention to the risk of alleles for type 2 diabetes, lacking evidence to clarify the risk for T2DM in different genetic models. Furthermore, 31 additional related papers [9–39] have been published after the publication of this meta-analysis; hence, the sample size became three times more.

Thus, this updated meta-analysis with trial sequential analysis (TSA) of all eligible studies was performed to assess the effect of the *KCNQ1* polymorphisms on T2DM risk. With 49 eligible articles included, we aimed to assess the associations between the 7 most studied polymorphisms of *KCNQ1* (rs2237892, rs2237895, rs2237897, rs2283228, rs231362, rs151290, and rs2074196) and the T2DM risk.

## 2. Methods and Analysis

**2.1. Study Identification.** Five electronic databases (PubMed, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang databases) were systematically searched up to July 3, 2019, using combinations of the following keywords: Diabetes Mellitus[MESH]/diabetes and *KCNQ1* and Polymorphism[MESH]/polymorphism/variant/genotype without language restriction. Some references might be inevitably missing during the database searching. Therefore, the corresponding items generated by PubMed have been recovered. The reference lists of the main related studies and review studies were reviewed to identify potential missing articles which are related to this topic.

**2.2. Selection Criteria.** Two authors (X-XY and M-QL) independently reviewed and selected the studies. The following inclusion criteria were used to select studies for this meta-analysis: (1) case-control study as study design; (2) T2DM as outcome; (3) evaluation of at least one of the following seven polymorphisms: rs2237892, rs2237895, rs2237897, rs2283228, rs231362, rs151290, and rs2074196; and (4) enough genotype information for data analysis. Studies with gestational diabetes or postoperative diabetes as the endpoint were excluded. Only the studies with the largest sample size were included when there were duplicate studies with overlapping data.

**2.3. Data Extraction.** For the included studies, the data were abstracted by two authors (XY and ML) using the same data extraction form as follows: first author, year of publication, country of origin or ethnicity of study participants, source of control groups, sample size of cases and controls, mean age and percentage of male of cases and controls, genotyping method, T2DM diagnostic criteria used, matching variables, and genotype and allele distributions of cases and controls.

**2.4. Quality Assessment.** The method, derived from a meta-analysis by Thakkinstian et al. [40] in 2011, was used to assess the methodological quality of the included case-control studies. The quality assessment criteria are shown in Supplementary Table 1. The quality for each included study based on their criteria was evaluated and given a score from 0 to 15. If a study was given a score of 9 or above, it was classified as a high-quality study. The same two authors mentioned above scored each study separately and independently, and the controversy about each study was discussed to reach a consensus.

**2.5. Quantitative Synthesis.** The chi-squared goodness-of-fit test was used to assess whether the gene frequency in controls was consistent with the Hardy-Weinberg equilibrium (HWE). The associations of seven polymorphisms of *KCNQ1* (rs2237892, rs2237895, rs2237897, rs2283228, rs231362, rs151290, and rs2074196) with the T2DM risk were evaluated by the collected odds ratios (ORs) and their 95% confidence intervals (95% CIs) according to the following five genetic models: (1) allele genetic model: M vs. W (“W” is the wild allele and “M” is the mutant allele); (2) homozygote genetic model: MM vs. WW; (3) heterozygote genetic model: WM vs. WW; (4) dominant genetic model: MM + WM vs. WW; and (5) recessive genetic model (MM vs. WM + WW). Heterogeneity between studies was assessed using Cochran’s  $Q$  and the  $I^2$  statistics. The random-effects model by the DerSimonian and Laird method was used in all analyses regardless of  $I^2$  values because it provides more conservative estimates [41].

The stratified analyses and meta-regression analyses were performed by races (Asian, Caucasian, or Mixed), HWE (yes or no), control sources (population or hospital), quality scores ( $<9$  or  $\geq 9$  points), year of publication ( $<2015$  or  $\geq 2015$ ), and number of participants ( $<500$  or  $\geq 500$ ), respectively. Sensitivity analysis by sequentially removing each study was also applied to verify the robustness of our findings

[42]. The published bias was tested by Egger's and Begg's regression asymmetry, as well as the funnel plots [43, 44].

All analyses mentioned above were conducted using Stata 11.0 software, and the test level was a  $P < 0.05$  on two sides.

**2.6. Trial Sequential Analysis.** The TSA tool was used to evaluate whether the quantitative results are reliable, and the required information size (RIS) was calculated to reduce type I error [45, 46]. TSA was performed for T2DM by anticipating a 20% relative risk reduction, a 5% of type I error, and an 80% of statistical test power [45].

**2.7. Genotype-Based mRNA Expression Analysis.** The *KCNQ1* mRNA expression data was retrieved for *KCNQ1* SNPs from the GTEx Portal database (<https://www.gtexportal.org/home/>). These data were used to evaluate the correlation between SNP genotypes and *KCNQ1* mRNA expression level alteration.

### 3. Results

**3.1. Study Selection and Characteristics.** In total, 942 articles were identified through the literature search (Figure 1). After the removal of duplicated articles and articles that did not meet the inclusion criteria, ultimately, 49 articles [7, 9–39, 47–63] (68,378 T2DM cases and 66,673 controls) were included in the qualitative synthesis.

The main characteristics for each included study are presented in Table 1, including studies from 15 different countries published from 2008 to 2018. The sample sizes ranged from 60 to 15,577 (median 900). There are 42,096 population-based controls and 24,577 hospital-based controls. The mean ages studied were 50.6 and 51.6 years for cases and controls, respectively. The proportions of male were 51.2% in the case group and 45.4% in the control group. Controls in 29 (52.7%) studies were matched at least by one variable (e.g., age, gender). Supplementary Table 2 shows the genotype distributions and HWE status of each polymorphism of all included studies.

Forty-two studies (50,747 cases and 50,023 controls) were included in the meta-analysis for rs2237892, 23 studies (42,127 cases and 38,276 controls) for rs2237895, 12 studies (18,808 cases and 18,847 controls) for rs2237897, and 10 studies (13,188 cases and 12,191 controls) for rs2283228. Besides, there are less than ten studies focused on rs231362, rs151290, and rs2074196, respectively.

**3.2. Quantitative Synthesis.** The summary of pooled estimates for the association between *KCNQ1* polymorphisms and T2DM risk is provided in Table 2 and Supplementary Fig. 1. Overall, the increased T2DM risks were generally found for rs2237892, rs2237895, rs2237897, rs2283228, rs151290, and rs2074196 under allele comparison, as well as all genetic models. For allele comparison, the ORs and their 95% CIs were 1.23 (1.14, 1.33) for the allele C of rs2237892, 1.21 (1.16, 1.27) for the allele C of rs2237895, 1.27 (1.11, 1.46) for the allele C of rs2237897, 1.25 (1.09, 1.42) for the allele A of rs2283228, 1.14 (1.03, 1.27) for the allele C of rs151290, and 1.31 (1.23, 1.39) for the allele G of rs2074196, respectively. On the contrary, no associa-

tion was found for rs231362 G/A polymorphism under any genetic model (OR: 1.16–1.51;  $P$  ranges: 0.12–0.39). Moderate to significant heterogeneity was observed for most of these polymorphisms (e.g.,  $I^2$  for allelic comparison ranged from 39.7% to 94.7%).

The results of subgroup analyses were revealed in Supplementary Table 3. When stratified by race, with studies conducted only among Asians for rs2237897, the risk effect was more evident among Asians than among Caucasians for rs2237892, rs2237895, rs2283228, and rs151290. All the risks persisted after excluding studies that deviated from HWE. When stratified by the sources of controls, the significant risk effects were only noticed in a population-based subgroup for rs2237892 and rs151290, whereas similar associations were observed for rs2237895 and rs2237897. In the subgroup analyses by quality scores and sample size, in general, the statistically significant results tended to occur in studies with high quality score and larger sample size. For rs2237892, rs2237895, and rs151290, the interaction of race on the association between *KCNQ1* polymorphisms and T2DM has been demonstrated by meta-regression analyses ( $P$  for regression: 0.041, 0.008, and 0.057, respectively; Supplementary Table 4).

**3.3. Sensitivity Analysis.** The sensitivity analysis indicated that most of our results in all genetic models for the 7 included polymorphisms were robust after excluding any single study, except for the results for the heterozygote comparison of rs2237897, the allelic comparison and recessive genetic model of rs231362, and the allelic comparison and recessive genetic model of rs151290, after excluding the study by Wang et al. [17], Ohshige et al. [59], and Yasuda et al. [48], respectively.

**3.4. Publication Bias.** Possible publication bias was assessed by Begg's and Egger's test, as well as the funnel plots. Begg's funnel plots of seven polymorphisms were basically symmetrical, and all  $P$  values for Egger's test were greater than 0.05. Our results indicated that publication bias does not appear in any comparison (Supplementary Fig. 2 and Supplementary Table 5).

**3.5. Trial Sequential Analysis Results.** The TSA was performed to investigate the relevance of *KCNQ1* seven gene polymorphisms with T2DM susceptibility. The allelic comparison was used to study all these polymorphisms. We noticed that the total number of cases and controls for all current relevant studies has exceeded the amount of information required for rs2237892, rs2237895, rs2283228, rs151290, and rs2074196 but insufficient for rs2237897 or rs231362 (Supplementary Fig. 3). Although the RIS has not yet been reached, the cumulative  $Z$ -curve crossed the monitoring boundary for rs2237897. Thus, the effect of rs2237897 on T2DM risk was stable. For rs231362, the RIS of 29011 has not yet been reached, but the limit of futility has been reached.

**3.6. Genotype-Based *KCNQ1* mRNA Expression Analysis Results.** Through the GTEx Portal website, mRNA expression data of three genotypes of rs2237892, rs2283228, and rs231362 were obtained. We found that the genotypes of




FIGURE 1: Flow diagram of the literature search and selection process.

the three SNPs were significantly correlated with altered *KCNQ1* gene expression (rs2237892 C/T:  $P = 3.8 * 10^{-5}$ ; rs2283228 A/C:  $P = 6.3 * 10^{-5}$ ; and rs231362 G/A:  $P = 3.5 * 10^{-5}$ ) (Supplementary Figs. 4–6).

#### 4. Discussion

To our knowledge, this meta-analysis is the most comprehensive study of the association between the *KCNQ1* seven gene polymorphisms and the T2DM risk. Our results provide evidence that six *KCNQ1* polymorphisms (rs2237892, rs2237897, rs151290, rs2283228, rs2074196, and rs2237895) might be significantly associated with increased T2DM risk. These significant associations are more pronounced among Asian populations and can be further confirmed by TSA.

Two previous meta-analyses [8, 64] focusing on the association between the *KCNQ1* polymorphisms and the risk of T2DM were published in 2013 and 2014, respectively. However, only the allele genetic model was analyzed in the meta-analysis by Liu et al. [8] and only one SNP of *KCNQ1* was studied in the meta-analysis by Li et al. [64]. But, seven SNPs of *KCNQ1* according to not only the allele genetic model but also the genetic models of the homozygote, heterozygote, dominant, and recessive com-

parison were performed in this meta-analysis. In the meta-analysis by Liu et al. [8], significantly increased T2DM risks were found for C allele of rs2237892 (OR = 1.31;  $P < 0.001$ ), C allele of rs2237895 (OR = 1.24;  $P < 0.001$ ), C allele of rs2237897 (OR = 1.34;  $P < 0.001$ ), A allele of rs2283228 (OR = 1.23;  $P < 0.001$ ), and G allele of rs231362 (OR = 1.10;  $P < 0.001$ ). Compared to the study by Liu et al. [8], 31 new articles [9–39] have been added to this meta-analysis, and the significant risks for rs151290 and rs2074196 were firstly found by us. Our results confirmed the effects of rs2237892, rs2237895, rs2237897, and rs2283228 on T2DM risk, but the result for rs231362 contradicted previous studies [8]. The following reasons may explain this discrepancy. First, the meta-analysis by Liu et al. [8] used a random-effects model only when there was heterogeneity; otherwise, a fixed-effects model was used. In this study, we always use the random-effects model, so our results are conservative. But for rs231362, with actual heterogeneity, that is, a random-effects model should be used. Second, Liu et al. [8] only studied the allele comparisons of *KCNQ1* polymorphisms (rs2237892, rs2237895, rs2237897, rs2283228, and rs231362) and did not conduct research on genotype distribution. Therefore, correspondingly, its literature selection criteria are more lenient. The inclusion of the

TABLE 1: Study characteristics from included studies in the meta-analysis.

First author	Year	Country	Ethnicity	Cases		Controls		Gender <sup>c</sup>	Control source	Matching variables	SNP(s) <sup>d</sup>	Score	
				N <sup>a</sup>	Age (y) <sup>b</sup>	N <sup>a</sup>	Age (y) <sup>b</sup>						
Lee YH	2008	Korea	Asian	908	58.2 ± 11.1	48.4	502	55.0 ± 9.4	53.6	Hospital	—	a	9
Unoki H (Japanese)	2008	Japan	Asian	5149	—	61.4	4176	—	47.6	Hospital	—	b, c, d	9
Unoki H (Chinese)	2008	China	Asian	1498	63.9 ± 9.7	49.1	1881	35.4 ± 11.2	44.0	Hospital	—	b, c, d	8
Unoki H (Danish)	2008	Denmark	Caucasian	4085	60.0 ± 9.8	59.3	5032	46.9 ± 9.1	53.7	Hospital	—	b, c, d	9
Yasuda K (Japanese)	2008	Japan	Asian	4378	—	—	4412	—	—	Population	—	a, b, f	12
Yasuda K (Chinese)	2008	China	Asian	1416	50.0 ± 13.7	40.4	1577	25.1 ± 14.2	46.1	Population	—	a, b	11
Yasuda K (Korean)	2008	Korea	Asian	758	59.2 ± 9.9	46.7	632	64.7 ± 3.6	45.4	Population	Gender	a, b	8
Yasuda K (Caucasian)	2008	Sweden	Caucasian	2830	57.9 ± 11.5	58.9	3740	57.4 ± 6.0	37.9	Population	Age	a, b	10
Hu C	2009	China	Asian	1769	61.1 ± 12.6	52.1	1734	57.4 ± 12.4	41.4	Hospital	—	a, b, c	7
Liu Y	2009	China	Asian	1912	63.9 ± 9.5	41.1	2041	58.1 ± 9.4	31.1	Population	—	a, b, c	10
Chen Z	2010	China	Asian	57	—	—	341	—	—	Hospital	—	a, b, c, d	6
Dehwh MAS	2010	China	Asian	223	53.9 ± 10.3	44.8	201	66.5 ± 8.0	44.3	Hospital	Gender	a	7
Han X	2010	China	Asian	1024	56.0 ± 12.0	52.7	1005	58.0 ± 9.0	34.1	Population	Age	a	11
Xu M	2010	China	Asian	66	—	—	652	—	—	Population	—	a	9
Wei Q	2010	China	Asian	133	56.0 ± 8.5	51.1	106	57.7 ± 11.1	50.9	Hospital	Age and gender	c, d, f	6
Zhang L	2010	China	Asian	100	53.0 ± 12.0	58.0	97	47.0 ± 18.0	53.6	Population	—	b	8
Been LF	2011	India and the USA	Caucasian	1428	—	—	1593	—	—	Population	—	a, b, e	13
Ohshige T	2011	Japan	Asian	2839	62.8	50.0	2125	51.6	50.0	Hospital	Gender	e	9
Saif-Ali R (Chinese)	2011	Malaysia	Asian	300	49.8 ± 7.4	51.0	230	52.9 ± 9.2	61.3	Hospital	Age	a, b, d	8
Saif-Ali R (Malay)	2011	Malaysia	Asian	234	48.5 ± 7.5	45.3	117	44.9 ± 10.7	45.8	Hospital	Age and gender	a, b, d	7
Tabara Y	2011	Japan	Asian	506	—	—	402	—	—	Hospital	—	a	8
Shi L	2011	China	Asian	171	56.1 ± 12.9	56.1	288	48.9 ± 11.6	60.1	Hospital	—	c, f	3
Van JV	2012	Netherlands	Caucasian	4620	64.3 ± 10.6	43.3	5285	51.1 ± 10.1	41.9	Population	Gender	a, b, f	12
Dai XP	2012	China	Asian	367	49.1 ± 10.8	49.9	214	47.6 ± 10.9	57.9	Hospital	Age	a, b	8
Iwata M	2012	Japan	Asian	724	64.9 ± 11.1	62.3	763	72.5 ± 9.0	47.1	Hospital	—	a, e	9
Lu S	2012	China	Asian	498	56.0 ± 7.0	59.6	402	49.0 ± 9.01	66.4	Hospital	—	e	8
Turki A	2012	Tunisia	Caucasian	900	61.2 ± 9.7	37.8	600	52.0 ± 11.9	45.5	Hospital	—	a, b, d, f	8
Gao X	2012	China	Asian	200	55.4 ± 12.8	55.5	200	53.7 ± 8.8	49.5	Hospital	Age	f	8
Wang J	2012	China	Asian	300	54.9 ± 13.2	42.3	100	52.6 ± 11.9	42.0	Hospital	Age and gender	e	7
Almawi WY	2013	Lebanon	Caucasian	995	58.6 ± 13.4	58.8	1076	57.3 ± 10.4	47.0	Hospital	Age	a, b	8
Wang H	2013	China	Asian	2533	53.3	59.6	2643	56.1	55.3	Population	Age and gender	a, b, c, d	10
Lin YD	2013	China	Asian	2925	58.2 ± 10.1	37.5	3281	56.6 ± 9.9	37.6	Population	Age and gender	a, b, c, e	11

TABLE 1: Continued.

First author	Year	Country	Ethnicity	Cases			Controls			Matching variables	SNP(s) <sup>d</sup>	Score	
				N <sup>a</sup>	Age (y) <sup>b</sup>	Gender <sup>c</sup>	N <sup>a</sup>	Age (y) <sup>b</sup>	Gender <sup>c</sup>				
Yang HL	2013	China	Asian	222	52.6 ± 20.5	55.9	140	59.4 ± 15.2	43.6	—	—	a	6
Yu WH	2013	China	Asian	9221	58.1	48.5	4052	48.6	40.7	Population	—	a, b	11
Bazzzi MD	2014	Saudi Arabia	Caucasian	90	50.7 ± 11.7	50.0	95	40.6 ± 4.6	52.6	Hospital	Age and gender	a	7
Sun ZH	2014	China	Asian	321	—	—	345	—	—	Hospital	—	c	8
Zhang LW	2014	China	Asian	349	49.5 ± 8.1	55.9	300	48.8 ± 11.7	60.3	Population	Age	a, c	11
Zhu AN	2014	China	Asian	238	58.3 ± 11.9	55.9	240	57.7 ± 11.6	55.8	Hospital	Age and gender	a	7
Khan IA	2015	India	Mixed	250	57.2 ± 8.2	55.2	250	53.9 ± 6.3	57.6	Hospital	Age and gender	d	7
Zhang W	2015	China	Asian	530	61.0 ± 12.6	53.0	452	58.8 ± 11.4	50.9	Hospital	Age and gender	a	8
Guo HL	2015	China	Asian	30	46.7 ± 7.3	63.3	30	46.6 ± 12.6	43.3	Hospital	Age	a	5
Shen Q	2015	China	Asian	922	58.5 ± 12.3	51.5	925	50.0 ± 7.5	46.4	Hospital	—	a	9
InterAct Consortium	2016	European countries	Mixed	6869	—	—	8708	—	—	Population	—	a	4
Cui LJ	2016	China	Asian	100	51.2 ± 11.6	55.0	100	49.9 ± 12.4	46.0	Hospital	Age	a, b	6
Gao K	2016	China	Asian	736	52.5 (43-61)	57.9	768	47.0 (39.0-57.0)	42.2	Population	—	f	11
Riobello C	2016	Spain	Caucasian	180	—	—	501	—	—	Population	—	a, b, e	11
Zhou X	2016	China	Asian	305	50.1 ± 6.4	49.5	200	48.9 ± 11.9	50.1	Hospital	Age and gender	a	8
Al-Shammari MS	2017	Saudi Arabia	Caucasian	320	51.5 ± 8.8	54.4	516	48.8 ± 6.9	56.0	Hospital	Age and gender	a, b, f	6
Baniasadian S	2018	Iran	Caucasian	77	—	45.5	90	—	48.9	Hospital	Gender	a	3
Plengvidhya N	2018	Thailand	Asian	500	57.2 ± 12.2	67.2	500	53.0 ± 8.4	71.2	Hospital	—	a	8
Chen JF	2018	China	Asian	84	54.5 ± 13.5	59.5	104	51.5 ± 11.2	55.8	Hospital	Age	a	6
Huang Q	2018	China	Asian	513	55.3 ± 6.6	28.5	502	55.2 ± 6.7	29.9	Population	Age and gender	a, f	13
Li YH (Uighur)	2018	China (Uighur)	Asian	282	48.3 ± 10.6	48.2	99	—	49.5	Population	Gender	a, e	8
Li YH (Chinese Han)	2018	China (Chinese Han)	Asian	293	59.4 ± 13.2	56.0	208	—	47.1	Population	—	a, e	10
Xu T	2018	China	Asian	100	50.6 ± 7.5	68.0	100	48.9 ± 8.4	57.0	Hospital	Age	a	5

SNP: single nucleotide polymorphism. <sup>a</sup>Number, <sup>b</sup>age at survey, <sup>c</sup>percentage of male, <sup>d</sup>SNPs; a: rs2237892; b: rs2237895; c: rs2237897; d: rs2283228; e: rs231362; f: rs151290.

TABLE 2: Total analysis of seven *KCNQ1* gene polymorphisms on T2DM risk.

Variables	N <sup>a</sup>	Cases/ controls	Allelic comparison				Homozygote comparison				Heterozygote comparison				Dominant genetic model				Recessive genetic model			
			OR (95% CI)	P <sup>b</sup>	I <sup>2</sup> (%)	P <sup>c</sup>	OR (95% CI)	P <sup>b</sup>	I <sup>2</sup> (%)	P <sup>c</sup>	OR (95% CI)	P <sup>b</sup>	I <sup>2</sup> (%)	P <sup>c</sup>	OR (95% CI)	P <sup>b</sup>	I <sup>2</sup> (%)	P <sup>c</sup>	OR (95% CI)	P <sup>b</sup>	I <sup>2</sup> (%)	P <sup>c</sup>
rs2237892	42	50,747/ 50,023	1.23 (1.14, 1.33)	<0.01	88.7	<0.01	1.69 (1.45, 1.96)	<0.01	80.2	<0.01	1.40 (1.28, 1.54)	<0.01	44.3	<0.01	1.55 (1.37, 1.76)	<0.01	71.9	<0.01	1.24 (1.12, 1.36)	<0.01	87.7	<0.01
rs2237895	23	42,127/ 38,276	1.21 (1.16, 1.27)	<0.01	74.1	<0.01	1.45 (1.32, 1.60)	<0.01	70.7	<0.01	1.23 (1.17, 1.29)	<0.01	48.6	0.01	1.28 (1.21, 1.36)	<0.01	65.9	<0.01	1.31 (1.22, 1.41)	<0.01	56.9	<0.01
rs2237897	12	18,808/ 18,847	1.27 (1.11, 1.46)	<0.01	92.5	<0.01	1.49 (1.09, 2.03)	<0.01	91.6	<0.01	1.19 (0.96, 1.48)	<0.01	84.2	<0.01	1.34 (1.02, 1.74)	0.03	91.2	<0.01	1.36 (1.16, 1.60)	<0.01	88.7	<0.01
rs2283228	10	13,188/ 12,191	1.25 (1.09, 1.42)	<0.01	81.8	<0.01	1.53 (1.25, 1.87)	<0.01	50.3	0.03	1.20 (1.08, 1.33)	<0.01	0.0	0.90	1.33 (1.18, 1.49)	<0.01	10.9	0.34	1.30 (1.10, 1.55)	<0.01	83.2	<0.01
rs231362	9	7666/ 6626	1.16 (0.83, 1.61)	0.39	94.7	<0.01	1.51 (0.90, 2.53)	<0.01	77.1	<0.01	1.22 (0.94, 1.58)	<0.01	24.5	0.23	1.33 (0.90, 1.97)	0.15	65.1	<0.01	1.22 (0.82, 1.8)	0.33	94.6	<0.01
rs151290	9	7808/ 7836	1.14 (1.03, 1.27)	0.02	71.2	<0.01	1.35 (1.09, 1.66)	<0.01	61.6	0.01	1.20 (1.04, 1.38)	<0.01	27.5	0.20	1.26 (1.08, 1.47)	<0.01	41.1	0.09	1.18 (1.02, 1.37)	0.03	73.5	<0.01
rs2074196	5	11,019/ 11,672	1.31 (1.23, 1.39)	<0.01	39.7	0.16	1.75 (1.54, 1.99)	<0.01	26.7	0.24	1.33 (1.22, 1.46)	<0.01	0.0	0.50	1.51 (1.37, 1.66)	<0.01	6.4	0.37	1.37 (1.27, 1.49)	<0.01	39.9	0.16

CI: confidence interval; T2DM: type 2 diabetes mellitus. <sup>a</sup>Number of comparisons. <sup>b</sup>P value of Z-test for the significant test. <sup>c</sup>P value of Q-test for the between-study heterogeneity test.

literature not included in this article may lead to statistically significant results for the rs231362 allele. Finally, the results of the study by Liu et al. [8] of Asians with rs231362 are consistent with this article—there is no significant association; significant association only occurred among Caucasians. For rs231362, the meta-analysis of Liu et al. [8] included only one study of Caucasians, which was a large-sample study. Therefore, we suspect that it caused the bias of the results of the overall population in the meta-analysis of Liu et al. [8]. There was no statistically significant association in the Caucasian subgroup in this meta-analysis, most likely because our relatively strict selection criteria—enough genotype information was required—did not allow the study to be included. Another study by Li et al. [64], with 9 studies included (6707 cases and 8129 controls), was only performed for rs2237892. They found a significant association between *KCNQ1* rs2237892 T polymorphism and T2DM in the Asian population under the allelic (OR = 1.350;  $P < 0.001$ ), recessive (OR = 0.650;  $P < 0.001$ ), dominant (OR = 1.450;  $P < 0.001$ ), and additive genetic models (OR = 1.346;  $P < 0.001$ ). The result of recessive genetic models contradicted with this meta-analysis (OR = 1.39;  $P < 0.001$ ). Similarly, compared to the study by Li et al. [64], 28 new articles [10, 13, 15–22, 24, 26, 27, 30–39, 48, 52, 60, 62, 63] have been added into the present meta-analysis; therefore, the existence of the inconsistent results between their study and ours is reasonable.

There is biological evidence supporting the hypothesis that *KCNQ1* might play a role in the susceptibility of T2DM. *KCNQ1*, encoding the alpha subunit of the  $IK_sK^+$  channel, is mainly expressed in the tissues or cells of the heart [65], as well as in pancreas islets, which plays an important role in the regulation of insulin secretion [7, 66]. The variants of *KCNQ1* are associated with impaired fasting glucose, beta-cell function, and impaired metabolic traits [7, 48]. Studies in INS-1 cells indicated that *KCNQ1*, assembling with *KCNE2* in insulin-secreting cells, could block the *KCNQ1*  $K^+$  channel with the sulfonamide analogue 293B and reduce 60% of whole beta-cell outward currents and that the presence of both 293B and tolbutamide could significantly increase the insulin secretion [6]. Animal studies revealed that increased *KCNQ1* protein expression could limit insulin secretion in pancreatic beta-cells through regulating potassium channel currents [67]. The previous study in vitro indicated that risk SNPs increase *KCNQ1* expression in pancreatic beta-cells, which increased the risk of T2DM [68]. And the research by Zeng et al. [69] showed that mutation of *KCNQ1* impaired capacity to maintain glucose homeostasis in vivo. A previous population-based study has indicated that the three polymorphisms of *KCNQ1* (rs2237892, rs2237895, and rs2237897) were significantly associated with the OGTT-derived insulin secretion index [70]. In addition, the rs151290 gene polymorphism was significantly related with the 30-minute C-peptide level during OGTT, the first-stage insulin secretion, and the proinsulin index [70]. It was also suggested that the methylation difference of *KCNQ1* was associated with insulin sensitivity and that CpG site-specific genetic variation predicted the methylation difference [71]. The molecular mechanism by which *KCNQ1* is associated with the risk of T2DM may be explained by the reasons mentioned above. We also found

that under different genotypes of rs2237892, rs2283228, or rs231362, the expression level of *KCNQ1* gene was significantly different. However, more research studies should be conducted to test the association between other SNPs with *KCNQ1* gene expression levels.

After stratified by race, the estimated risks were more evident among Asians than among Caucasians for rs2237892, rs2237895, rs2283228, and rs151290. Metaregression analyses also confirmed these phenomena. According to our data, the significantly lower proportion in the frequency of minor alleles in controls for *KCNQ1* polymorphisms was observed among Asians and Caucasians (e.g., in rs2237892, 5.6% vs. 34.6%; in rs2283228, 6.5% vs. 37.5%; and in rs151290, 25.1% vs. 41.8%), which might have led to a difference in the results between the two ethnicities.

Since 2008, many related original studies or meta-analyses on the association of *KCNQ1* and T2DM have been published. However, none of these meta-analyses has conducted the TSA, suggesting the lack of support from TSA. Accompanied with our results, the TSA in our study showed that the RIS had been achieved in each SNP. Thus, the findings of the present meta-analysis are suggested to be robust.

Following the PRISMA guidelines, our meta-analysis was carried out through conducting a comprehensive literature search, using Egger's and Begg's regression asymmetry test and funnel plot to assess potential publication bias, and exploring the potential sources of heterogeneity by subgroup and sensitivity analyses. Our findings persisted after excluding studies that deviated from HWE. This meta-analysis had included the largest number of existing original studies in this area; therefore, the statistical testing power was relatively higher than before. In addition, a TSA method has been used to test the robustness of our findings, which might further ensure our results.

The findings of the present study should be mentioned with some limitations. Firstly, we noted the heterogeneity in the overall effect estimated for most of the SNPs which have been quantitatively synthesized. However, we had tried to explore the potential sources of heterogeneity by subgroup or metaregression analyses, and we found that ethnicity might be the main potential source of between-study heterogeneity in rs2237892, rs2237895, rs2283228, and rs151290. Secondly, in the sensitivity analysis, we found that the results of two genetic models for rs231362 would reach significance after removing the study by Ohshige et al. [59]. Nevertheless, the sample size of this study by Ohshige et al. [59] is the largest for rs231362, indicating that this result was needed to be further confirmed. Thirdly, the number of pooled studies for the subgroup analyses was relatively small for rs2074196 ( $n = 4$ ), and it might have attenuated the statistical power and confined the conduction of subgroup analyses. Fourthly, all the included studies for rs2237897 are derived from Asians, and more studies with diverse race are needed to confirm its role on T2DM risk. Finally, due to the lack of information about the age of onset of a large number of studies, we cannot assess the effect of the *KCNQ1* polymorphism on the T2DM according to the age at baseline, which may also affect the further interpretation of our study.



In conclusion, our results demonstrate that the C allele of rs2237892, rs2237895, and rs151290, the A allele of rs2283228, and the G allele of rs2074196, but not C allele of rs231362 of *KCNQ1* gene, might play significant roles in the susceptibility of T2DM, especially among Asian population. Still, larger and well-designed studies including other risk factors are warranted to validate the findings from the present analysis.

## Conflicts of Interest

The authors state that the study was conducted without any commercial or financial relationship.

## Authors' Contributions

FZ and YY designed this study. YZ and XG searched databases and collected full-text papers. XY and ML independently reviewed and selected the studies. XY and ML extracted and analyzed data. SZ provided guidance for statistical analysis. XY, ML, YL, and WS wrote the manuscript. FZ and YY reviewed the manuscript. Xiao-xuan Yu and Min-qi Liao contributed equally to this work.

## Supplementary Materials

Supplementary Fig. 1: forest plots of overall analysis between the *KCNQ1* polymorphisms and the risk of T2DM in homozygote comparison. Supplementary Fig. 2: funnel plots of overall analysis between the *KCNQ1* polymorphisms and the risk of T2DM in homozygote comparison. Supplementary Fig. 3: trial sequential analysis of the association between the *KCNQ1* polymorphisms and the risk of T2DM in allelic comparison. Supplementary Fig. 4: genotype-based mRNA expression alteration for *KCNQ1* rs2237892 polymorphism in subcutaneous adipose based on data from the GTEx Portal database (<https://www.gtexportal.org/home/>). Supplementary Fig. 5: genotype-based mRNA expression alteration for *KCNQ1* rs2283228 polymorphism in subcutaneous adipose based on data from the GTEx Portal database (<https://www.gtexportal.org/home/>). Supplementary Fig. 6: genotype-based mRNA expression alteration for *KCNQ1* rs231362 polymorphism in cultured fibroblasts based on data from the GTEx Portal database (<https://www.gtexportal.org/home/>). Supplementary Table 1: score of quality assessment. Supplementary Table 2: *KCNQ1* polymorphism genotype distribution among T2DM cases and controls of the included studies. Supplementary Table 3: stratified analysis of seven *KCNQ1* gene polymorphisms on T2DM. Supplementary Table 4: the metaregression analysis of homozygous *KCNQ1* gene on T2DM. Supplementary Table 5: publication bias tests (Egger's funnel plot for publication bias test) for seven *KCNQ1* gene polymorphisms. (*Supplementary Materials*)

## References

- [1] Y. Zheng, S. H. Ley, and F. B. Hu, "Global aetiology and epidemiology of type 2 diabetes mellitus and its complications," *Nature Reviews Endocrinology*, vol. 14, no. 2, pp. 88–98, 2018.
- [2] K. Ogurtsova, J. D. da Rocha Fernandes, Y. Huang et al., "IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040," *Diabetes Research and Clinical Practice*, vol. 128, pp. 40–50, 2017.
- [3] S. O'Rahilly, I. Barroso, and N. J. Wareham, "Genetic factors in type 2 diabetes: the end of the beginning?," *Science*, vol. 307, no. 5708, pp. 370–373, 2005.
- [4] T. Ohshige, Y. Tanaka, S. Araki et al., "A single nucleotide polymorphism in *KCNQ1* is associated with susceptibility to diabetic nephropathy in Japanese subjects with type 2 diabetes," *Diabetes Care*, vol. 33, no. 4, pp. 842–846, 2010.
- [5] X. D. Chen, Y. J. Yang, S. Y. Li et al., "Several polymorphisms of *KCNQ1* gene are associated with plasma lipid levels in general Chinese populations," *PLoS One*, vol. 7, no. 3, article e34229, 2012.
- [6] S. Ullrich, J. Su, F. Ranta et al., "Effects of IKs channel inhibitors in insulin-secreting INS-1 cells," *Pflügers Archiv*, vol. 451, no. 3, pp. 428–436, 2005.
- [7] H. Unoki, A. Takahashi, T. Kawaguchi et al., "SNPs in *\_KCNQ1\_* are associated with susceptibility to type 2 diabetes in East Asian and European populations," *Nature Genetics*, vol. 40, no. 9, pp. 1098–1102, 2008.
- [8] J. Liu, F. Wang, Y. Wu et al., "Meta-analysis of the effect of *KCNQ1* gene polymorphism on the risk of type 2 diabetes," *Molecular Biology Reports*, vol. 40, no. 5, pp. 3557–3567, 2013.
- [9] X. P. Dai, Q. Huang, J. Y. Yin et al., "*KCNQ1* gene polymorphisms are associated with the therapeutic efficacy of repaglinide in Chinese type 2 diabetic patients," *Clinical and Experimental Pharmacology & Physiology*, vol. 39, no. 5, pp. 462–468, 2012.
- [10] M. Iwata, S. Maeda, Y. Kamura et al., "Genetic risk score constructed using 14 susceptibility alleles for type 2 diabetes is associated with the early onset of diabetes and may predict the future requirement of insulin injections among Japanese individuals," *Diabetes Care*, vol. 35, no. 8, pp. 1763–1770, 2012.
- [11] W. Juan, *Association between *KCNQ1* gene and *IDE* gene and type 2 diabetes in Chinese Han people*, Tianjin Medical University, 2012.
- [12] S. Lu, Y. Xie, K. Lin et al., "Genome-wide association studies-derived susceptibility loci in type 2 diabetes: confirmation in a Chinese population," *Clinical and Investigative Medicine*, vol. 35, no. 5, article E327, 2012.
- [13] A. Turki, N. Mtiraoui, A. S. al-Busaidi, M. Khirallah, T. Mahjoub, and W. Y. Almawi, "Lack of association between genetic polymorphisms within *KCNQ1* locus and type 2 diabetes in Tunisian Arabs," *Diabetes Research and Clinical Practice*, vol. 98, no. 3, pp. 452–458, 2012.
- [14] G. Xing, L. Dongmei, W. Yan et al., "Association studies of *KCNQ1* gene polymorphism and type 2 diabetes mellitus in Huaihai region," *Chinese General Practice*, vol. 15, no. 27, pp. 3139–3142, 2012.
- [15] W. Y. Almawi, R. Nemr, S. H. Keleshian et al., "A replication study of 19 GWAS-validated type 2 diabetes at-risk variants in the Lebanese population," *Diabetes Research and Clinical Practice*, vol. 102, no. 2, pp. 117–122, 2013.
- [16] Y. Hailian, *The study of early screening of type 2 diabetes in Chinese Han population*, Ningbo University, 2013.
- [17] H. Wang, K. Miao, J. Zhao et al., "Common Variants in *KCNQ1* Confer Increased Risk of Type 2 Diabetes and Contribute to the Diabetic Epidemic in East Asians: A Replication

- and Meta-Analysis,” *Annals of Human Genetics*, vol. 77, no. 5, pp. 380–391, 2013.
- [18] Y. Weihui, *The association of KCNQ1 genetic variants with type 2 diabetes-related traits and therapeutic efficacy of oral antidiabetic drugs in the Chinese population*, Shanghai Jiao Tong University, 2013.
- [19] Y.-d. Lin, Y. Qian, M.-h. Dong et al., “Association of polymorphisms of potassium voltage-gated channel, KQT-like subfamily, member 1 and type 2 diabetes in Jiangsu province, China,” *Chinese Journal of Preventive Medicine*, vol. 47, no. 6, pp. 538–541, 2013.
- [20] Z. Anna, Y. Xuexue, W. Yingsong, Z. Zhongxiang, L. Ming et al., “Association study of single nucleotide polymorphisms in KCNQ1 and susceptibility of type 2 diabetes,” *Journal of Tropical Medicine*, vol. 14, no. 1, pp. 41–45, 2014.
- [21] M. D. Bazzi, F. A. Nasr, M. S. Alanazi et al., “Association between FTO, MC4R, SLC30A8, and KCNQ1 gene variants and type 2 diabetes in Saudi population,” *Genetics and Molecular Research*, vol. 13, no. 4, pp. 10194–10203, 2014.
- [22] L. W. Zhang, J. Li, F. F. Duan et al., “Association of TCF7L2, KCNQ1 gene polymorphism with type 2 diabetes,” *Journal of Environmental Health*, vol. 31, no. 2, pp. 156–159, 2014.
- [23] S. Zehua, Z. Liufu, Y. Zhiping, W. Xiuli et al., “Association analysis of KCNQ1 gene polymorphisms with pioglitazone response in Chinese Han type 2 diabetes patients,” *Anhui Medical Journal*, vol. 35, no. 5, pp. 626–629, 2014.
- [24] G. Huiling, *Screening susceptibility genes of pre-diabetes and the study on the relationship between susceptibility genes and TCM syndrome of pre-diabetes*, Chengdu University of TCM, 2015.
- [25] I. A. Khan, K. K. Vattam, P. Jahan, K. K. Mukkavali, Q. Hasan, and P. Rao, “Correlation between KCNQ1 and KCNJ11 gene polymorphisms and type 2 and post-transplant diabetes mellitus in the Asian Indian population,” *Genes & Diseases*, vol. 2, no. 3, pp. 276–282, 2015.
- [26] S. Qin, L. Wenya, H. Xingpo, D. Yanbei et al., “Association of KCNJ11 and KCNQ1 genes with type 2 diabetes mellitus in Chinese population,” *Jiangsu Med J*, vol. 41, no. 2, pp. 157–159, 2015.
- [27] W. Zhang, H. Wang, X. Guan, Q. Niu, and W. Li, “Variant rs2237892 of KCNQ1 is potentially associated with hypertension and macrovascular complications in type 2 diabetes mellitus in a Chinese Han population,” *Genomics, Proteomics & Bioinformatics*, vol. 13, no. 6, pp. 364–370, 2015.
- [28] The InterAct Consortium, “Investigation of gene-diet interactions in the incretin system and risk of type 2 diabetes: the EPIC-InterAct study,” *Diabetologia*, vol. 59, no. 12, pp. 2613–2621, 2016.
- [29] L. J. Cui, X. Y. Chang, L. Y. Zhu et al., “Relationship between the polymorphisms in KCNQ1 and type 2 diabetes in Chinese Kazakh population,” *Genetics and Molecular Research*, vol. 15, no. 2, 2016.
- [30] K. Gao, J. Wang, L. Li et al., “Polymorphisms in four genes (KCNQ1 rs151290, KLF14 rs972283, GCKR rs780094 and MTNR1B rs10830963) and their correlation with type 2 diabetes mellitus in han Chinese in Henan province, China,” *International Journal of Environmental Research and Public Health*, vol. 13, no. 3, p. 260, 2016.
- [31] C. Riobello, J. Gómez, H. Gil-Peña et al., “KCNQ1 gene variants in the risk for type 2 diabetes and impaired renal function in the Spanish Renastur cohort,” *Molecular and Cellular Endocrinology*, vol. 427, pp. 86–91, 2016.
- [32] X. Zhou, J. Zhu, Z. Bao et al., “A variation in KCNQ1 gene is associated with repaglinide efficacy on insulin resistance in Chinese Type 2 Diabetes Mellitus Patients,” *Scientific Reports*, vol. 6, no. 1, article 37293, 2016.
- [33] M. S. Al-Shammari, R. Al-Ali, N. Al-Balawi et al., “Type 2 diabetes associated variants of KCNQ1 strongly confer the risk of cardiovascular disease among the Saudi Arabian population,” *Genetics and Molecular Biology*, vol. 40, no. 3, pp. 586–590, 2017.
- [34] S. Baniasadian, S. Farajnia, and B. Jafari, “Frequency of KCNQ1 variant rs2237892 in type 2 diabetes in East Azerbaijan population, northwest of Iran,” *Acta Medica Iranica*, vol. 56, no. 2, pp. 90–94, 2018.
- [35] C. Jianfeng and P. Tianrong, “Association between KCNQ1 gene rs2237892 polymorphism and type 2 diabetes mellitus in Han nationality in Hefei area,” *Acta Universitatis Medicinalis Anhui*, vol. 53, no. 1, pp. 110–113, 2018.
- [36] N. Plengvidhya, C. Chanprasert, N. Chongiaroen, P. T. Yenchitsomanus, M. Homsanit, and W. Tangittipokin, “Impact of KCNQ1, CDKN2A/2B, CDKAL1, HHEX, MTNR1B, SLC30A8, TCF7L2, and UBE2E2 on risk of developing type 2 diabetes in Thai population,” *BMC Medical Genetics*, vol. 19, no. 1, p. 93, 2018.
- [37] H. Qin, W. Qi, C. Haiyan, W. Qingfeng, L. Xiaohua, Y. Zhaokang et al., “Association between KQT sub-family potassium voltage-gated channel number 1 genepolymorphism and type 2 diabetes mellitus in Ganzhou residents,” *Journal of Nanchang University (Medical Science)*, vol. 58, no. 2, pp. 27–31+41, 2018.
- [38] X. Ting, P. Bailing, and D. Pingying, “Correlation study between gene polymorphism of KCNQ1 and SLC30A8 and type 2 diabetes mellitus,” *China Modern Doctor*, vol. 56, no. 9, pp. 1–4, 2018.
- [39] L. Yanhui, Z. Tingting, and L. Hao, “Association analysis between genetic polymorphisms of KCNQ1 and SRR genes with type 2 diabetes mellitus in the Uygur and Han population,” *Chinese Journal of Diabetes*, vol. 26, no. 7, pp. 534–542, 2018.
- [40] A. Thakkinian, G. J. McKay, M. McEvoy et al., “Systematic review and meta-analysis of the association between complement component 3 and age-related macular degeneration: a HuGE review and meta-analysis,” *American Journal of Epidemiology*, vol. 173, no. 12, pp. 1365–1379, 2011.
- [41] N. Mantel and W. Haenszel, “Statistical aspects of the analysis of data from retrospective studies of disease,” *Journal of the National Cancer Institute*, vol. 22, no. 4, pp. 719–748, 1959.
- [42] A. Tobias, “Assessing the influence of a single study in the meta-analysis estimate,” *Stata Technical Bulletin*, vol. 47, pp. 15–17, 1999.
- [43] M. Egger, G. D. Smith, M. Schneider, and C. Minder, “Bias in meta-analysis detected by a simple, graphical test,” *BMJ*, vol. 315, no. 7109, pp. 629–634, 1997.
- [44] P. P. da Silva Pereira, F. A. F. Da Mata, A. C. G. Figueiredo, K. R. C. de Andrade, and M. G. Pereira, “Maternal active smoking during pregnancy and low birth weight in the Americas: a systematic review and meta-analysis,” *Nicotine & Tobacco Research*, vol. 19, no. 5, pp. 497–505, 2017.
- [45] H. He, W. T. Cao, Y. H. Zeng et al., “Lack of associations between the FTO polymorphisms and gestational diabetes: a

- meta-analysis and trial sequential analysis,” *Gene*, vol. 677, pp. 169–175, 2018.
- [46] L. B. Holst, M. W. Petersen, N. Haase, A. Perner, and J. Wetterslev, “Restrictive versus liberal transfusion strategy for red blood cell transfusion: systematic review of randomised trials with meta-analysis and trial sequential analysis,” *BMJ*, vol. 350, no. 9, article h1354, 2015.
- [47] Y. H. Lee, E. S. Kang, S. H. Kim et al., “Association between polymorphisms in *SLC30A8*, *HHEX*, *CDKN2A/B*, *IGF2BP2*, *FTO*, *WFS1*, *CDKAL1*, *KCNQ1* and type 2 diabetes in the Korean population,” *Journal of Human Genetics*, vol. 53, no. 11–12, pp. 991–998, 2008.
- [48] K. Yasuda, K. Miyake, Y. Horikawa et al., “Variants in *KCNQ1* are associated with susceptibility to type 2 diabetes mellitus,” *Nature Genetics*, vol. 40, no. 9, pp. 1092–1097, 2008.
- [49] C. Hu, C. Wang, R. Zhang et al., “Variations in *KCNQ1* are associated with type 2 diabetes and beta cell function in a Chinese population,” *Diabetologia*, vol. 52, no. 7, pp. 1322–1325, 2009.
- [50] Y. Liu, D. Z. Zhou, D. Zhang et al., “Variants in *KCNQ1* are associated with susceptibility to type 2 diabetes in the population of mainland China,” *Diabetologia*, vol. 52, no. 7, pp. 1315–1321, 2009.
- [51] Z. Chen, X. Zhang, G. Ma, Q. Qian, and Y. Yao, “Association study of four variants in *KCNQ1* with type 2 diabetes mellitus and premature coronary artery disease in a Chinese population,” *Molecular Biology Reports*, vol. 37, no. 1, pp. 207–212, 2010.
- [52] M. A. S. Dehwhah, S. Zhang, K. Qu, H. Huang, A. Xu, and Q. Huang, “*KCNQ1* and type 2 diabetes: study in Hubei Han Chinese and meta-analysis in East Asian populations,” *Genes & Genomics*, vol. 32, no. 4, pp. 327–334, 2010.
- [53] X. Han, Y. Luo, Q. Ren et al., “Implication of genetic variants near *SLC30A8*, *HHEX*, *CDKAL1*, *CDKN2A/B*, *IGF2BP2*, *FTO*, *TCF2*, *KCNQ1*, and *WFS1* in type 2 diabetes in a Chinese population,” *BMC Medical Genetics*, vol. 11, no. 1, 2010.
- [54] Z. Li, *A Study on the Association of Type 2 Diabetes Mellitus with KCNQ1 Polymorphisms and Evaluation of Intervention Effect*, Bengbu Medical College, 2010.
- [55] W. Qun, *A study on the association of type 2 diabetes mellitus with KCNQ1 polymorphisms and evaluation of intervention effect*, Hebei Medical University, 2010.
- [56] M. Xu, Y. Bi, Y. Xu et al., “Combined effects of 19 common variations on type 2 diabetes in Chinese: results from two community-based studies,” *PLoS One*, vol. 5, no. 11, article e14022, 2010.
- [57] L. F. Been, S. Ralhan, G. S. Wander et al., “Variants in *KCNQ1* increase type II diabetes susceptibility in South Asians: a study of 3,310 subjects from India and the US,” *BMC Medical Genetics*, vol. 12, no. 1, p. 18, 2011.
- [58] S. Li, *A study on the association of KCNQ1 gene polymorphisms and GLP-1 with type 2 diabetes mellitus and diabetic nephropathy*, Kunming Medical University, 2011.
- [59] T. Ohshige, M. Iwata, S. Omori et al., “Association of new loci identified in European genome-wide association studies with susceptibility to type 2 diabetes in the Japanese,” *PLoS One*, vol. 6, no. 10, article e26911, 2011.
- [60] R. Saif-Ali, I. S. Ismail, Z. al-Hamodi et al., “*KCNQ1* haplotypes associate with type 2 diabetes in Malaysian Chinese subjects,” *International Journal of Molecular Sciences*, vol. 12, no. 9, pp. 5705–5718, 2011.
- [61] R. Saif-Ali, S. Muniandy, Z. Al-Hamodi et al., “*KCNQ1* variants associate with type 2 diabetes in Malaysian Malay subjects,” *Annals of the Academy of Medicine, Singapore*, vol. 40, no. 11, pp. 488–492, 2011.
- [62] Y. Tabara, H. Osawa, R. Kawamoto et al., “Genotype risk score of common susceptible variants for prediction of type 2 diabetes mellitus in Japanese: the Shimanami Health Promoting Program (J-SHIP) study: Development of type 2 diabetes mellitus and genotype risk score,” *Metabolism*, vol. 60, no. 11, pp. 1634–1640, 2011.
- [63] J. V. van Vliet-Ostaptchouk, T. W. van Haeften, G. W. D. Landman et al., “Common variants in the type 2 diabetes *KCNQ1* gene are associated with impairments in insulin secretion during hyperglycaemic glucose clamp,” *PLoS One*, vol. 7, no. 3, article e32148, 2012.
- [64] Y. Y. Li, X. M. Wang, and X. Z. Lu, “*KCNQ1* rs2237892 C→T gene polymorphism and type 2 diabetes mellitus in the Asian population: a meta-analysis of 15,736 patients,” *Journal of Cellular and Molecular Medicine*, vol. 18, no. 2, pp. 274–282, 2014.
- [65] M. P. Lee, J. D. Ravenel, R. J. Hu et al., “Targeted disruption of the *Kvlqt1* gene causes deafness and gastric hyperplasia in mice,” *The Journal of Clinical Investigation*, vol. 106, no. 12, pp. 1447–1455, 2000.
- [66] Q. Qi, H. Li, R. J. F. Loos et al., “Common variants in *KCNQ1* are associated with type 2 diabetes and impaired fasting glucose in a Chinese Han population,” *Human Molecular Genetics*, vol. 18, no. 18, pp. 3508–3515, 2009.
- [67] L. Liu, F. Wang, H. Lu, X. Ren, and J. Zou, “Chromanol 293B, an inhibitor of *KCNQ1* channels, enhances glucose-stimulated insulin secretion and increases glucagon-like peptide-1 level in mice,” *Islets*, vol. 6, no. 4, article e962386, 2014.
- [68] K. Yamagata, T. Senokuchi, M. Lu et al., “Voltage-gated  $K^+$  channel *KCNQ1* regulates insulin secretion in MIN6  $\beta$ -cell line,” *Biochemical and Biophysical Research Communications*, vol. 407, no. 3, pp. 620–625, 2011.
- [69] H. Zeng, M. Guo, T. Zhou et al., “An isogenic human ESC platform for functional evaluation of genome-wide association-study-identified diabetes genes and drug discovery,” *Cell Stem Cell*, vol. 19, no. 3, pp. 326–340, 2016.
- [70] K. Mussig, H. Staiger, F. Machicao et al., “Association of type 2 diabetes candidate polymorphisms in *KCNQ1* with incretin and insulin secretion,” *Diabetes*, vol. 58, no. 7, pp. 1715–1720, 2009.
- [71] U. J. Shah, W. Xie, A. Flyvbjerg et al., “Differential methylation of the type 2 diabetes susceptibility locus *KCNQ1* is associated with insulin sensitivity and is predicted by CpG site specific genetic variation,” *Diabetes Research and Clinical Practice*, vol. 148, pp. 189–199, 2019.